Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Virus hepatitis B, A, non-A, non-B.

S Sherlock1

  • 1Department of Surgery, Royal Free Hospital School of Medicine, University of London, U.K.

Journal of Hepatology
|March 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune cholangitis.

Clinics in liver disease·2001
Same author

A la carte interferon for hepatitis C?

Hepatology (Baltimore, Md.)·2000
Same author

The hepatic flaviviridae: summary.

Journal of viral hepatitis·2000
Same author

Biotechnologies and liver diseases.

Forum (Genoa, Italy)·1999
Same author

Carbon dioxide embolism following diagnostic hysteroscopy.

Anaesthesia and intensive care·1999
Same author

Focal nodular hyperplasia in a young female.

Journal of hepatology·1999

Hepatitis B vaccination is recommended for all infants, especially in high-risk regions, with potential benefits in routine childhood programs. Booster shots are likely needed 5-7 years post-vaccination to ensure long-term protection.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Hepatitis B vaccine is safe and effective but has limitations in disease prevention.
  • Hepatitis A causes significant epidemics with considerable economic impact, particularly in Western Europe.
  • Non-A, non-B hepatitis includes epidemic (enterically transmitted) and parenteral forms, each with distinct viral characteristics and serological markers.

Purpose of the Study:

  • To evaluate the impact and recommendations for Hepatitis B vaccination programs.
  • To discuss the ongoing development of vaccines for Hepatitis A.
  • To describe the causative agents and transmission of non-A, non-B hepatitis.

Main Methods:

  • Review of existing data on Hepatitis B vaccine efficacy and impact.

Related Experiment Videos

  • Discussion of Hepatitis A epidemiology and the search for new vaccines.
  • Characterization of viruses causing epidemic and parenteral non-A, non-B hepatitis and identification of associated antibodies.

    • Main Results:

    • Mass vaccination of infants is recommended in high-risk areas for Hepatitis B.
    • Routine childhood immunization for Hepatitis B may be effective in low-risk areas, with a likely need for booster doses.
    • Hepatitis A vaccines are under development to replace immune globulin prophylaxis.
    • Epidemic non-A, non-B hepatitis is caused by an enterically transmitted virus, while parenteral non-A, non-B hepatitis is linked to a specific viral genomic clone.

    Conclusions:

    • Hepatitis B vaccination strategies should be tailored to risk levels, with consideration for routine childhood programs and booster injections.
    • Effective vaccines for Hepatitis A are needed to combat widespread epidemics.
    • Further research into non-A, non-B hepatitis viruses is crucial for developing targeted prevention and treatment strategies.